University of California-San Francisco · Biomedical EngineeringThe Kallikrein Lab
Michael John Evans · San Francisco, California
Research Focus
Dr. Michael John Evans' lab focuses on developing new radiotherapy strategies to treat prostate cancer by utilizing the unique biochemistry of human kallikrein 2 (hK2). The lab is pioneering novel low molecular weight peptides that can target cancer cells more effectively and safely, offering enhanced therapeutic benefits over current treatments. This research aims not only to improve tumor imaging and assessment but also to create targeted radiopharmaceuticals that can better deliver radiation directly to cancer cells while minimizing side effects.
prostate cancertheranosticsradiotherapyhuman kallikrein 2peptide drugsmolecular targetingPET imagingradiopharmaceuticalsbiochemical targeting
Research Aims
3AIM 01Develop a new class of radiopharmaceuticals for prostate cancer targeting.
AIM 02Evaluate the safety and efficacy of hK2 targeting peptides in clinical settings.
AIM 03Assess the tumor imaging ability of the developed peptides in cancer patients.
Skills the Lab Values
PET imagingpeptide synthesisradiolabeling techniquestumor xenograft modelsclinical trial designpharmacokineticsanimal handlingdata analysis with imaging softwarebiochemical assays
Output against the department
Publications336top 27% of dept.162nd of 595
this lab
most publishedleast published
Citations13ktop 28% of dept.165th of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.